145 related articles for article (PubMed ID: 3177252)
1. The effect of surgical debulking on the response of patients with ovarian carcinoma to chemotherapy.
McDermott DF; Jaffe EA; Coleman M; Pasmantier MW
Am J Clin Oncol; 1988 Oct; 11(5):520-3. PubMed ID: 3177252
[TBL] [Abstract][Full Text] [Related]
2. Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study.
Nagasaka K; Kawana K; Tomio K; Tsuruga T; Mori-Uchino M; Miura S; Tanikawa M; Miyamoto Y; Ikeda Y; Sone K; Adachi K; Matsumoto Y; Arimoto T; Oda K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2015 May; 41(5):755-62. PubMed ID: 25421004
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
6. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
7. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging.
Shimada M; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Minagawa Y; Ishihara K; Takeuchi Y; Okada M; Terakawa N
Int J Gynecol Cancer; 2005; 15(4):601-5. PubMed ID: 16014112
[TBL] [Abstract][Full Text] [Related]
8. [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin].
Kawaguchi R; Furukawa N; Morimoto Y; Ohi M; Osawa T; Koike H; Miyake T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):619-22. PubMed ID: 15114712
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian cancer from the standpoint of medical oncology].
Kato Y; Katsumata N
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1017-21. PubMed ID: 17637538
[TBL] [Abstract][Full Text] [Related]
10. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
12. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
13. [Management of ovarian cancer].
Dauplat J
Cancer Radiother; 2001 Nov; 5 Suppl 1():149s-161s. PubMed ID: 11797275
[TBL] [Abstract][Full Text] [Related]
14. Alternating combination chemotherapy for stages III and IV ovarian carcinoma.
Young JA; Johnson A; Kroener J; Koziol JA; Saltzstein S; Yon JL; Campbell TN; Lucas W; Green MR
J Clin Oncol; 1984 Dec; 2(12):1317-20. PubMed ID: 6512580
[TBL] [Abstract][Full Text] [Related]
15. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
16. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
[TBL] [Abstract][Full Text] [Related]
18. [Is there a standard therapy in advanced ovarian carcinoma?].
Köchli OR
Praxis (Bern 1994); 1999 Jan; 88(4):123-5. PubMed ID: 10067114
[No Abstract] [Full Text] [Related]
19. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
20. [First line chemotherapy of advanced epithelial ovarian cancer].
Lhommé C; Even C; Morice P; Balleyguier C; Petrella M; Gouy S; Uzan C; Duvillard P; Pautier P
Bull Cancer; 2009 Dec; 96(12):1207-13. PubMed ID: 19948450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
